Literature DB >> 7060886

Reduced suppressor cell activity in intestinal lymphocytes from patients with Crohn's disease.

R L Goodacre, J Bienenstock.   

Abstract

Suppressor cell activity in intestinal lymphocytes was investigated by a coculture assay with autologous peripheral blood lymphocytes. Greater than 45% suppression was found in 7 out of 10 patients without Crohn's disease. Reduced suppressor cell activity was found in intestinal lymphocytes isolated from 7 out of 8 patients with Crohn's disease. Intestinal lymphocytes from patients with Crohn's disease demonstrated a significantly greater response to phytohemagglutinin-P than lymphocytes isolated from non-Crohn's patients. However, this difference could not be explained by alterations in proportions of T lymphocytes as intestinal T lymphocytes from non-Crohn's disease patients (54%) were not significantly different from those found in patients with Crohn's disease (57%). Indomethacin, a prostaglandin synthetase inhibitor, decreased the proliferative response of intestinal lymphocytes to phytohemagglutinin-P whereas the response of peripheral blood lymphocytes was enhanced, thus providing further evidence that intestinal lymphocytes may represent a functionally distinct population from circulating lymphocytes. Cimetidine, a H2-receptor antagonist, had no effect on the response of intestinal lymphocytes to phytohemagglutinin-P. These results provide evidence to support the concept that disturbed immunoregulation at the mucosal level is found in Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060886

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

1.  Antigen induced suppression in peripheral blood and lamina propria mononuclear cells in inflammatory bowel disease.

Authors:  H R Dalton; P Hoang; D P Jewell
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

Review 2.  The immunology of inflammatory bowel disease.

Authors:  J R Lowes; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Isolation of intestinal mononuclear cells: factors released which affect lymphocyte viability and function.

Authors:  P R Gibson; A Hermanowicz; H J Verhaar; D J Ferguson; A L Bernal; D P Jewell
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

4.  Phenotype and functional properties of Vicia villosa agglutinin (VVA) binding T cells in patients with Crohn's disease: detection of contrasuppressor activity in patients lacking extra-intestinal manifestations, abscesses and fistulas.

Authors:  A Raedler; H J Lenz; K Sandgren; A de Weerth; S Enversen; S Schreiber; H G Thiele; H Greten
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

5.  Lymphoglandular complexes in the diseased colon.

Authors:  A D O'Leary; E C Sweeney
Journal:  Ir J Med Sci       Date:  1987-12       Impact factor: 1.568

6.  Immunological studies on Crohn's disease. V. Enumeration of circulating lymphocytes subsets using monoclonal antibodies.

Authors:  N Okabe; K Fujita; M Yamasaki; T Yao; S Tsuru
Journal:  Gastroenterol Jpn       Date:  1985-10

7.  Immunoelectron microscopic localization of HLA-DR antigen in control small intestine and colon and in inflammatory bowel disease.

Authors:  I Hirata; L L Austin; W H Blackwell; J R Weber; W O Dobbins
Journal:  Dig Dis Sci       Date:  1986-12       Impact factor: 3.199

8.  Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon.

Authors:  G B McDonald; D P Jewell
Journal:  J Clin Pathol       Date:  1987-03       Impact factor: 3.411

9.  Loss of suppressor T-cells in active inflammatory bowel disease.

Authors:  N J Godin; D B Sachar; R Winchester; C Simon; H D Janowitz
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

10.  In vitro immunoglobulin secretion by normal human gastrointestinal mucosal tissues, and alterations in patients with inflammatory bowel disease.

Authors:  V A Danis; A D Harries; R V Heatley
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.